PECULIARITIES OF СHOLINERGIC REGULATION OF THE HEART OF DIFFERENT SEX RATS IN THE DAMAGE OF MYOCARDIUM BY DEXAMETAZON AND USING OF L-CARNITINE FOR CORRECTION
DOI:
https://doi.org/10.11603/1811-2471.2019.v0.i1.10060Keywords:
dexamethasone, L-carnitine, myocardial damage, vagus nerve, bradycardia intensity, acetylcholineAbstract
Glucocorticoids are often used in the treatment of chronic inflammatory diseases, but their long-term use is accompanied by the development of complications. One of these complications is myocardial damage. Searching of new medications of cardioprotection involves influencing on various links of pathogenesis, including the physiological mechanisms that provide natural protection. The cholinergic link in the regulation of heart activity by the autonomic nervous system is able to provide such protection to the heart and the searching of substances, which modulates the activity of this link determines the topicality of this study.
The aim – to estimate the intensity of bradycardia in acetylcholine injection into the jugular vein and electrical stimulation of the peripheral segment of the vagus nerve by electric current under conditions of heart damage by dexamethasone and action of L-carnitine in animals of different sexes.
Material and Methods. Experiments were performed on 48 adult white outbred rats of different sexes, which were divided into 4 groups. The intensity of bradycardia was studied using electrocardiography on the computer complex CardioLab CE and electrical stimulator ECL-2
Results and Discussion. Dexamethasone (at a dose of 350 µg/kg of animal body weight per os) similarly acts on the cholinergic activity of the sinus node of the heart of rats of different sexes – reduces the sensitivity of the cholinergic receptors. On the background of dexamethasone, the cholinergic activity of the sinus node of animals of different sexes in exposed of L-carnitine (200 mg/kg of animal weight per os) varies differently – in females, the sensitivity of cholinergic receptors decreases sharply with a compensatory increase in the neurotransmitter release rate into the presynaptic cleft. In males, the sensitivity of cholinergic receptors remains low with a moderate decrease in the intensity of acetylcholine release.
References
Lutay, M.I., Parkhomenko, A.N., & Lysenko, A.F. (2013). Mezhdunarodnyy registr CLARIFY bolnykh so stabilnoy ishemicheskoy boleznyu serdtsa v Ukraine: Osobennosti, problemy, perspektivy. Ukr. Kardiol. Zhurn. – Ukrainian Cardiology Journal, 3, 13-21 [in Russian].
Kopple, J.D. (2002). L-carnitine ameliorates gentamicin-induced renal injury in rats. Nephrology Dialysis Transplantation,17 (12), 2122-2131.
Ferrari, R., Merli, E., Cicchitelli, G., Mele, D., Fucili, A., & Ceconi, C. (2004). Therapeutic Effects of l-Carnitine and Propionyl-l-carnitine on Cardiovascular Diseases: A Review. Annals of the New York Academy of Sciences,1033 (1), 79-91.
Noordali, H., Loudon, B.L., Frenneaux, M.P., & Madhani, M. (2018). Cardiac metabolism — A promising therapeutic target for heart failure. Pharmacology & Therapeutics, 182, 95-114.
Ringseis, R., Keller, J., & Eder, K. (2011). Role of carnitine in the regulation of glucose homeostasis and insulin sensitivity: Evidence from in vivo and in vitro studies with carnitine supplementation and carnitine deficiency. European Journal of Nutrition, 51 (1), 1-18.
Astashkyn, E.Y., & Hlezer, M.H. (2016). L-karnitina na oksydativnyy stress pri serdechnososudystykh zabolevanyyakh [The effect of L-carnitine on oxidative stress in cardiovascular diseases]. Meditsynskyy Sovet – Medical Board, 10, 104-110 [in Russian].
Bai, Y.Y., Sun, L., Liu, J. H., & Sun, R. T. (2009). L-Carnitine and cardiovascular disease: From basic science to clinical application. Cardiology,114, 1s, 128.
Dinicolantonio, J.J., Lavie, C.J., Fares, H., Menezes, A.R., & Okeefe, J.H. (2013). L-Carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clinic Proceedings, 88 (6), 544-551.
Roy, S.G., De, P., Mukherjee, D., Chander, V., Konar, A., Bandyopadhyay, D., & Bandyopadhyay, A. (2009). Excess of glucocorticoid induces cardiac dysfunction via activating angiotensin II pathway. Cellular Physiology and Biochemistry, 24 (1-2), 1-10.
